Biology of Human Papillomavirus Infections in Head and Neck Carcinogenesis

Head and Neck Pathology

Volumn 6, Issue SUPPL. 1, 2012, Pages 3-15

  Rautava, Jaana ^a,b   Syrjänen, Stina ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cancer; Diagnosis; HPV; Mouth mucosa; Mouth neoplasms; Oncogenic proteins; Oral potentially malignant disorders; Papillomavirus infections; Transmission; Viral; Warts

Indexed keywords

CELL TRANSFORMATION; HEAD AND NECK TUMOR; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRUS INFECTION; PHYSIOLOGY; REVIEW; VIROLOGY;

CELL TRANSFORMATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRUS INFECTIONS;

EID: 84864123408     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-012-0367-2     Document Type: Review

References (62)

1. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004; 324: 17-27.
2. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2: 342-50.
3. Thierry F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology. 2009; 384: 375-9.
4. Ruutu M, Peitsaro P, Johansson B, Syrjänen S. Transcriptional profiling of a human papillomavirus 33-positive squamous epithelial cell line which acquired a selective growth advantage after viral integration. Int J Cancer. 2002; 100: 318-26.
5. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005; 32(Suppl 1): S7-15. Review.
6. Wang HK, Duffy AA, Broker TR, Chow LT. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev. 2009; 23: 181-94.
7. Letian T, Tianyu Z. Cellular receptor binding and entry of human papillomavirus. Cellular receptor binding and entry of human papillomavirus. Virol J. 2010; 7: 2. Review.
8. Kajiji S, Tamura RN, Quaranta V. A novel integrin (alpha 6 beta 4) from human epithelial cells suggests a fourth family of integrin adhesion receptors. EMBO J. 1989; 8: 673-80.
9. Shafti-Keramat S, Handisurya A, Kriehuber E, et al. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol. 2003; 77: 13125-35.
10. Day PM, Lowy DR, Schiller JT. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology. 2003; 307: 1-11.
11. Bousarghin L, Touzé A, Sizaret PY, Coursaget P. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J Virol. 2003; 77: 3846-50.
12. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991; 185: 251-7.
13. Kämper N, Day PM, Nowak T, et al. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol. 2006; 80: 759-68.
14. Sapp M, Bienkowska-Haba M. Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J. 2009; 276: 7206-16. Review.
15. Syrjänen S. HPV infections and tonsillar carcinoma. J Clin Pathol. 2004; 57: 449-55. Review.
16. Kim SH, Koo BS, Kang S, Park K, Kim H, Lee KR, Lee MJ, Kim JM, Choi EC, Cho NH. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer. 2007; 120: 1418-25.
17. Surján L. Immunohistochemical markers of tonsillar crypt epithelium. Acta Otolaryngol. 1988; 105: 60-3.
18. Fujimura Y, Takeda M, Ikai H, Haruma K, Akisada T, Harada T, Sakai T, Ohuchi M. The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling. Virchows Arch. 2004; 444: 36-42.
19. Ghittoni R, Accardi R, Hasan U, et al. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 2010; 40: 1-13.
20. Hamid NA, Brown C, Gaston K. The regulation of cell proliferation by the papillomavirus early proteins. Cell Mol Life Sci. 2009; 66: 1700-17.
21. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010; 10: 550-60. Review.
22. Finzer P, Aguilar-Lemarroy A, Rösl F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett. 2002; 188: 15-24. Review.
23. Münger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004; 78: 11451-60.
24. Javier RT, Rice AP. Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses. J Virol. 2011; 85: 11544-56. Review.
25. van den Heuvel S, Dyson NJ. Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol. 2008; 9: 713-24. Review.
26. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63: 1129-36.
27. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990; 248: 76-9.
28. Schlegel R, Wade-Glass M, Rabson MS, Yang YC. The E5 transforming gene of bovine papillomavirus encodes a small, hydrophobic polypeptide. Science. 1986; 233: 464-7.
29. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol. 1993; 67: 4521-32.
30. Disbrow GL, Hanover JA, Schlegel R. Endoplasmic reticulum-localized human papillomavirus type 16 E5 protein alters endosomal pH but not trans-Golgi pH. J Virol. 2005; 79: 5839-46.
31. Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol. 1993; 67: 6929-36.
32. Peitsaro P, Ruutu M, Syrjänen S, Johansson B. Divergent expression changes of telomerase and E6/E7 mRNA, following integration of human papillomavirus type 33 in cultured epithelial cells. Scand J Infect Dis. 2004; 36: 302-4.
33. Duensing S, Münger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer. 2004; 109: 157-62.
34. McLaughlin-Drubin ME, Münger K. The human papillomavirus E7 oncoprotein. Virology. 2009; 384: 335-44. Review.
35. White EA, Sowa ME, Tan MJ, et al. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A. 2012; 109: E260-7.
36. Maufort JP, Shai A, Pitot HC, Lambert PF. A role for HPV16 E5 in cervical carcinogenesis. Cancer Res. 2010; 70: 2924-31.
37. Kanodia S, Fahey LM, Kast M. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007; 7: 79-89.
38. Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo MS, Borzacchiello G. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer. 2011; 10: 140. Published online 2011 November 11. doi: 10. 1186/1476-4598-10-140.
39. Syrjänen K, Syrjänen S, Lamberg M, et al. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg. 1983; 12: 418-24.
40. Chang F, Syrjänen S, Nuutinen J, et al. Detection of human papillomavirus (HPV) DNA in oral squamous cell carcinomas by in situ hybridization and polymerase chain reaction. Arch Dermatol Res. 1990; 282: 493-7.
41. Hansson BG, Rosenquist K, Antonsson A, et al. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol. 2005; 125: 1337-44.
42. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus. N Engl J Med. 2010; 363: 24-53.
43. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck. 2012. doi: 10. 1002/hed. 22015. [Epub ahead of print].
44. Syrjänen S, Lodi G, von Bültzingslöwen I, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis. 2011; Suppl 1: 58-72. Review.
45. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Part B: biological agents LYON, France 2011, Volume 100B pp. 278-80.
46. Dayyani F, Etzel CJ, Liu M, et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010; 2: 15. Published online 2010 June 29. doi: 10. 1186/1758-3284-2-15.
47. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100: 261-9.
48. Sinha P, Logan HL, Mendenhall WM. Human papillomavirus, smoking, and head and neck cancer. Am J Otolaryngol. 2012; 33: 130-6.
49. Jabbar S, Strati K, Shin MK, Pitot HC, Lambert PF. Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology. 2010; 407: 60-7.
50. Song S, Liem A, Miller JA, Lambert PF. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology. 2000; 267: 141-50.
51. Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A. 2006; 103: 14152-7.
52. Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Kalantari M, Dalianis T. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer. 2002; 102: 152-8.
53. Rautava J, Syrjänen S. Human papillomavirus infections in the oral mucosa. J Am Dent Assoc. 2011; 142: 905-14. Review.
54. Koskimaa HM, Kurvinen K, Costa S, et al. Molecular markers implicating early malignant events in cervical carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2003-12.
55. Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog. 2009; 5(4): e1000397.
56. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011; 11: 9-22. Review.
57. Strati K, Lambert PF. Human papillomavirus association with head and neck cancers: understanding virus biology and using it in the development of cancer diagnostics. Expert Opin Med Diagn. 2008; 2: 11-20.
58. Lewis JS Jr, Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol. 2010; 34: 1088-96.
59. Saha A, Kaul R, Murakami M, Robertson ES. Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention. Cancer Biol Ther. 2010; 10: 961-78. Review.
60. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002; 2(331-341): 61.
61. Rampias T, Boutati E, Pectasides E, et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res. 2010; 8: 433-43.
62. Wilting SM, Smeets SJ, Snijders PJ, et al. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics. 2009; 2: 32. doi: 10. 1186/1755-8794-2-32.